It has been shown that the primary striatal dopaminergic hypofunction which
is at the origin of Parkinson's disease, results in a secondary hyperactiv
ity of glutamatergic neurotransmission. In the search for a therapy of Park
inson's disease, ionotropic, mainly NMDA, receptor antagonists were found t
o have moderately beneficial, yet also some undesirable side-effects. There
fore the present study was aimed at determining whether some metabotropic g
lutamate receptor (mGluR) ligands may have antiparkinsonian effects in the
haloperidol-induced muscle rigidity. To this end three mGluR ligands were u
sed: the potent and selective mGluR I antagonist (RS)-1-aminoindan-1,5-dica
rboxylic acid (AIDA), the mixed group II agonist/group I antagonist (S)-4-c
arboxy-3-hydroxyphenyl-glycine ((S)-4-C3HPG), and the potent group II agoni
st (+)-2-aminobicyclo[3.1.0.]hexane-2,6,dicarboxylic acid (LY354740). Only
LY354740 penetrated the brain from the periphery; for this reason other dru
gs were injected bilaterally into the rostral striatum or nucleus accumbens
. The muscle tone was recorded by a mechanomyographic/electromyographic (MM
G/EMG) method which measured the resistance of a rat's hind foot and the EM
G reflex response of its muscles to passive movements. (S)-4C3KPG (5 and 15
mu g/0.5 mu l) and LY354740 (5 and 10 mg/kg i.p.) diminished the muscle ri
gidity induced by haloperidol (1 mg/kg i.p.). AIDA (0.5-15 mu g/0.5 mu l) i
njected into the striatum was only slightly effective in the highest dose u
sed. However, when injected into the nucleus accumbens AIDA (15 mu g/0.5 mu
l) significantly and strongly counteracted the haloperidol-induced muscle
rigidity. Our results suggest that stimulation of group II striatal mGluRs
seems to play a major role in diminution of parkinsonian-like muscle rigidi
ty. However, it seems that the antagonism of group I mGluRs located in the
nucleus accumbens may also be of importance to the antiparkinsonian effect.